BACKGROUND: Inherited leukodystrophies are progressive, debilitating neurological disorders with few treatment options and high mortality rates. Our objective was to determine national variation in the costs for leukodystrophy patients and to evaluate differences in their care. METHODS: We developed an algorithm to identify inherited leukodystrophy patients in deidentified data sets using a recursive tree model based on International Classification of Disease, 9th Edition, Clinical Modification, diagnosis and procedure charge codes. Validation of the algorithm was performed independently at two institutions, and with data from the Pediatric Health Information System (PHIS) of 43 US children's hospitals, for a 7-year period between 2004 and 2010. RESULTS: A recursive algorithm was developed and validated, based on six International Classification of Disease, 9th Edition, Clinical Modification, codes and one procedure code that had a sensitivity up to 90% (range 61-90%) and a specificity up to 99% (range 53-99%) for identifying inherited leukodystrophy patients. Inherited leukodystrophy patients comprise 0.4% of admissions to children's hospitals and 0.7% of costs. During 7 years, these patients required $411 million of hospital care, or $131,000/patient. Hospital costs for leukodystrophy patients varied at different institutions, ranging from two to 15 times more than the average pediatric patient. There was a statistically significant correlation between higher volume and increased cost efficiency. Increased mortality rates had an inverse relationship with increased patient volume that was not statistically significant. CONCLUSIONS: We developed and validated a code-based algorithm for identifying leukodystrophy patients in deidentified national datasets. Leukodystrophy patients account for $59 million of costs yearly at children's hospitals. Our data highlight potential to reduce unwarranted variability and improve patient care.
BACKGROUND:Inherited leukodystrophies are progressive, debilitating neurological disorders with few treatment options and high mortality rates. Our objective was to determine national variation in the costs for leukodystrophypatients and to evaluate differences in their care. METHODS: We developed an algorithm to identify inherited leukodystrophypatients in deidentified data sets using a recursive tree model based on International Classification of Disease, 9th Edition, Clinical Modification, diagnosis and procedure charge codes. Validation of the algorithm was performed independently at two institutions, and with data from the Pediatric Health Information System (PHIS) of 43 US children's hospitals, for a 7-year period between 2004 and 2010. RESULTS: A recursive algorithm was developed and validated, based on six International Classification of Disease, 9th Edition, Clinical Modification, codes and one procedure code that had a sensitivity up to 90% (range 61-90%) and a specificity up to 99% (range 53-99%) for identifying inherited leukodystrophypatients. Inherited leukodystrophypatients comprise 0.4% of admissions to children's hospitals and 0.7% of costs. During 7 years, these patients required $411 million of hospital care, or $131,000/patient. Hospital costs for leukodystrophypatients varied at different institutions, ranging from two to 15 times more than the average pediatric patient. There was a statistically significant correlation between higher volume and increased cost efficiency. Increased mortality rates had an inverse relationship with increased patient volume that was not statistically significant. CONCLUSIONS: We developed and validated a code-based algorithm for identifying leukodystrophypatients in deidentified national datasets. Leukodystrophypatients account for $59 million of costs yearly at children's hospitals. Our data highlight potential to reduce unwarranted variability and improve patient care.
Authors: Scott P Narus; Rajendu Srivastava; Ramkiran Gouripeddi; Oren E Livne; Peter Mo; Jonathan P Bickel; David de Regt; Joseph W Hales; Eric Kirkendall; Richard L Stepanek; Jamie Toth; Ron Keren Journal: AMIA Annu Symp Proc Date: 2011-10-22
Authors: Clint Nelson; Michael B Mundorff; E Kent Korgenski; Cameron J Brimley; Rajendu Srivastava; Joshua L Bonkowsky Journal: J Pediatr Date: 2012-10-13 Impact factor: 4.406
Authors: Jay G Berry; Annapurna Poduri; Joshua L Bonkowsky; Jing Zhou; Dionne A Graham; Chelsea Welch; Heather Putney; Rajendu Srivastava Journal: PLoS Med Date: 2012-01-17 Impact factor: 11.069
Authors: Stefan Kölker; Dries Dobbelaere; Johannes Häberle; Peter Burgard; Florian Gleich; Marshall L Summar; Steven Hannigan; Samantha Parker; Anupam Chakrapani; Matthias R Baumgartner Journal: JIMD Rep Date: 2015-02-22
Authors: Francesco Gavazzi; Laura Adang; Amy Waldman; Amanda K Jan; Geraldine Liu; Scott A Lorch; Sara B DeMauro; Justine Shults; Samuel R Pierce; Elizabeth Ballance; Tracy Kornafel; Ann Harrington; Allan M Glanzman; Adeline Vanderver Journal: Pediatr Neurol Date: 2021-09-24 Impact factor: 4.210
Authors: Laura A Adang; Omar Sherbini; Laura Ball; Miriam Bloom; Anil Darbari; Hernan Amartino; Donna DiVito; Florian Eichler; Maria Escolar; Sarah H Evans; Ali Fatemi; Jamie Fraser; Leslie Hollowell; Nicole Jaffe; Christopher Joseph; Mary Karpinski; Stephanie Keller; Ryan Maddock; Edna Mancilla; Bruce McClary; Jana Mertz; Kiley Morgart; Thomas Langan; Richard Leventer; Sumit Parikh; Amy Pizzino; Erin Prange; Deborah L Renaud; William Rizzo; Jay Shapiro; Dean Suhr; Teryn Suhr; Davide Tonduti; Jacque Waggoner; Amy Waldman; Nicole I Wolf; Ayelet Zerem; Joshua L Bonkowsky; Genevieve Bernard; Keith van Haren; Adeline Vanderver Journal: Mol Genet Metab Date: 2017-08-20 Impact factor: 4.797
Authors: Sara E Grineski; Danielle X Morales; Timothy Collins; Jacob Wilkes; Joshua L Bonkowsky Journal: J Racial Ethn Health Disparities Date: 2020-02-24
Authors: Holly M Anderson; Jacob Wilkes; E Kent Korgenski; Michael A Pulsipher; Anne J Blaschke; Adam L Hersh; Rajendu Srivastava; Joshua L Bonkowsky Journal: Ann Clin Transl Neurol Date: 2014-05-01 Impact factor: 4.511